In this trial of >18K patients with ACS, they were randomized to ticagrelor (an oral reversible direct inhibitor of adenosine diphosphate) or clopidogrel. At 1 year, rates of MI/CVA/Vascular death were lower in the ticagrelor group (10%) than the clopidogrel group (12%) with no difference in overall bleeding (abstract). Ticagrelor is superior to clopidogrel in reducing events post-ACS, and is pending FDA approval.

This entry was posted on Friday, September 4th, 2009 at 12:26 pm and is filed under Other. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.